Agreed,
@gmac55. Of course, an option for Cryosite would be to advise the market when it enters a material clinical trials contract, be it with Imugene, Pfizer or AstraZeneca or the clutch of other 'sticky' global players it deals with daily.
Under previous, marketing-oriented management, it would. Under the present management it won't.
Again, I'd be grateful if CTE embraced the four-letter word NEWS and used it's potent ASX platform to regularly advise shareholders and potential investors on what's happening in the $1.5b Australian clinical trials industry and, importantly, what the group is achieving.
I suggest that elevating the group's profile would materially hoist it's humble market cap of ~$19.4m.
